|  |  |  | Patients |  | ||
---|---|---|---|---|---|---|---|
Study | Design | Treatment groups | APACHE II score | N | Age (Y) | Male/female | Intervention |
Nelson 1998 [37] | 2 parallel groups, 71 centers | G-CSF | 16.1 | 380 | 63.4 ± 16.4 | 235/145 | Filgrastim: 300 μg/d, subcutaneous, 10 days |
 |  | Placebo | 17.0 | 376 | 64.5 ± 15.2 | 254/122 |  |
Nelson 2000 [38] | 2 parallel groups, 105 centers | G-CSF | 14.5 | 237 | 61.1 ± 17.3 | 138/99 | Filgrastim: 300 μg/d, subcutaneous, 10 days |
 |  | Placebo | 15.5 | 243 | 62.3 ± 17.4 | 153/90 |  |
Tanaka 2001 [39] | 2 parallel groups, 1 center | G-CSF | 18.0 | 12 | 49.8 ± 6.4 | 11/1 | Lenograstim: 2 μg/kg/d, intravenous, 5 days |
 |  | Placebo | 15.9 | 13 | 54.8 ± 5.7 | 9/4 |  |
Wund 2001 [40] | 2 parallel groups, 3 centers | G-CSF | 25.0 | 12 | 49.5 | 8/4 | Filgrastim: 300 μg/d, intravenous, 10 days |
 |  | Placebo | 31.5 | 6 | 56.5 | 4/2 |  |
Presneill 2002 [41] | 2 parallel groups, 1 center | GM-CSF | 12 | 10 | 62 | 7/3 | Molgramostim:3 μg/kg/d, intravenous, 5 days |
 |  | Placebo | 10 | 8 | 46.5 | 6/2 |  |
Root 2003 [42] | 2 parallel groups, 96 centers | G-CSF | 24.3 ± 7.5 | 348 | 58.9 ± 17.1 | 240/108 | Filgrastim: 300 μg/d, intravenous, 5 days |
 |  | Placebo | 24.2 ± 6.9 | 353 | 60.0 ± 16.4 | 247/106 |  |
Hartma 2005 [43] | 2 parallel groups, 1 center | G-CSF | 13 | 13 | 66 | 2/11 | Filgrastim: 300 μg/d, subcutaneous, 7 days |
 |  | Placebo | 12.5 | 16 | 63 | 5/11 |  |
Rosen 2005 [44] | 2 parallel groups, 1 center | GM-CSF | _ | 18 | 56 | 8/10 | Sargramostim: 3 μg/kg/d, intravenous, 3 days |
 |  | Placebo | _ | 15 | 52 | 9/6 |  |
Orozco 2006 [45] | 2 parallel groups, 1 center | GM-CSF | 7.3 ± 6.3 | 28 | 43.2 ± 15.9 | 13/15 | Molgramostim: 3 μg/kg/d, subcutaneous, 4 days |
 |  | Placebo | 7.7 ± 6.4 | 30 | 49.2 ± 16.5 | 16/14 |  |
Cheng 2007 [46] | 2 parallel groups, 1 center | G-CSF | 22 | 30 | 61 | _ | Lenograstim: 263 μg/d, intravenous, 3 days |
 |  | Placebo | 22 | 30 | 57 | _ |  |
Stephens 2008 [47] | 2 parallel groups, 1 center | G-CSF | 22.5 ± 7.6 | 81 | 51.0 ± 15.1 | 45/36 | Lenograstim: 263 μg/d, intravenous, 10 days |
 |  | Placebo | 23.4 ± 8.2 | 83 | 48.9 ± 16.1 | 45/38 |  |
Meisel 2009 [48] | 2 parallel groups, 3 centers | GM-CSF | 21.3 ± 6.1 | 19 | 64.0 ± 13.6 | 16/3 | GM-CSF: 4 μg/kg/d, subcutaneous, 8 days |
 |  | Placebo | 22.5 ± 6.6 | 19 | 63.3 ± 14.2 | 15/4 |  |